エピソード
-
In this final episode, Chiara De Biase and Jean Marco trace the journey of transluminal angioplasty from Charles Dotter in the US to Andreas Grüntzig in Europe. Grüntzig's vision was to apply balloon angioplasty to treat coronary artery stenosis, for which he defined clear goals and working axes. With determination, he collaborated with experts to develop a double-lumen balloon catheter and tested its safety and feasibility in animals and during bypass surgery. Despite scepticism, Grüntzig successfully performed the first percutaneous transluminal coronary angioplasty in September 1977, realising his dream.
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode, Chiara De Biase and Jean Marco discuss how Eberhard Zeitler, inspired by Dotter's work, introduced the method in Germany. Grüntzig, known for his solid medical background and empathetic demeanor, received crucial support from colleagues. His determination, teamwork, and commitment led to the development of a flexible catheter with a non-compliant balloon, which resulted in the first human transluminal balloon angioplasty in 1974. Stay tuned to learn how he then moved from the leg to the coronaries in the next episode!
Hosted on Acast. See acast.com/privacy for more information.
-
エピソードを見逃しましたか？
-
In this podcast, Chiara De Biase and Jean Marco highlight three key reasons for Charles Dotter's failure to spread his method widely in the USA. Firstly, his position as a radiologist, not a vascular surgeon; secondly, his aggressive presentation of the technique, coupled with limited patient data; and lastly, his unconventional approach to developing tools and the lack of clear objectives.
Stay tuned to discover how Dotter's method made its way to Europe in the next episode.
Hosted on Acast. See acast.com/privacy for more information.
-
In this first episode, Chiara De Biase and Jean Marco discuss Dotter's groundbreaking contributions, including the first interventional transluminal angioplasty in 1964, which revolutionized vascular medicine. Despite Dotter's visionary work, his name was nearly forgotten.
Why was Dotter's disruptive innovation initially rejected? Stay tuned to uncover more about Dotter's legacy and the evolution of interventional medicine.
Hosted on Acast. See acast.com/privacy for more information.
